Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$84.93 USD

84.93
2,385,980

+0.61 (0.72%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Apr 7, 2021

by Zacks Equity Research

Companies in The News Are: ILMN, NVAX, MRNA, BP.

Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine

by Zacks Equity Research

Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.

Rimmi Singhi headshot

5 Stocks With High Earnings Yield for Superior Returns

by Rimmi Singhi

Check out high earnings yield stocks including AA, USAK, GIII, MU and MRNA for a standout portfolio.

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FAD

Cidara (CDTX) Inks Agreement With J&J for Influenza Therapies

by Zacks Equity Research

Cidara (CDTX) and J&J ink a collaboration agreement to develop influenza candidates with the potential to provide protection against all influenza strains.

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $132.55, moving +1.22% from the previous trading session.

The Zacks Analyst Blog Highlights: Comcast, Netflix, PepsiCo, General Electric and Moderna

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Comcast, Netflix, PepsiCo, General Electric and Moderna

Pfizer (PFE)/BioNTech COVID-19 Vaccine 100% Effective in Teens

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) report 100% efficacy for their COVID-19 vaccine in teenagers aged 12 to 15.

Sweta Jaiswal, FRM headshot

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

by Sweta Jaiswal, FRM

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Sheraz Mian headshot

Top Research Reports for Comcast, Netflix & PepsiCo

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), Netflix,Inc. (NFLX) and PepsiCo, Inc. (PEP).

Sweta Jaiswal, FRM headshot

Moderna ETFs to Gain on Positive 'Real-World' Study Data

by Sweta Jaiswal, FRM

Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.

Sweta Jaiswal, FRM headshot

Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?

by Sweta Jaiswal, FRM

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.

J&J's (JNJ) Pharma Unit & COVID-19 Vaccine Key to 2021 Growth

by Zacks Equity Research

J&J's (JNJ) Pharma unit is performing above-market levels, helped by new drugs and label expansion of blockbuster drugs, Imbruvica, Darzalex & Stelara. Its COVID-19 vaccine is expected to contribute to sales growth.

David Borun headshot

Bull of the Day: Owens and Minor (OMI)

by David Borun

This medical logistics company made big gains in 2020 - and is poised to keep heading higher.

Why Is Moderna (MRNA) Down 10.2% Since Last Earnings Report?

by Zacks Equity Research

Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bristol-Myers (BMY) Announces Results From Opdivo Combo Study

by Zacks Equity Research

Bristol-Myers (BMY) announces encouraging primary results from a study, evaluating a fixed-dose combination of relatlimab and immuno-oncology drug, Opdivo, in metastatic or unresectable melanoma.

AstraZeneca (AZN) Reports New Efficacy Data on COVID-19 Vaccine

by Zacks Equity Research

AstraZeneca (AZN) reports new efficacy data for its COVID-19 vaccine in the Unites States following criticism for providing outdated data.

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $133.33 in the latest trading session, marking a +1.31% move from the prior day.

Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?

AstraZeneca (AZN) COVID-19 Vaccine Data May Be Outdated Per NIH

by Zacks Equity Research

NIH's Data Safety Monitoring Board questions AstraZeneca's (AZN) COVID-19 vaccine data from its late-stage U.S. study.

Kinjel Shah headshot

Will the Fourth COVID-19 Vaccine in U.S. Get FDA Nod Soon?

by Kinjel Shah

Interim data from a U.S. late-stage study on AstraZeneca's (AZN) COVID-19 vaccine shows that the candidate was, on average, about 79% effective in preventing COVID-19.

Sweta Killa headshot

5 S&P 500 Stocks That Zoomed 200% Plus From Pandemic Lows

by Sweta Killa

After touching a low of 2,191 on Mar 23, 2020, the S&P 500 staged a strong comeback and is on track to hit a new milestone of 4,000.

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $143.74, moving +1.61% from the previous trading session.

Sweta Killa headshot

1-Year Tour From Market Crash to Boom: 5 Top ETFs

by Sweta Killa

The stock market staged a strong rebound from the lows and is currently hitting new highs with the major bourses crossing new milestones.

Moderna (MRNA) Begins Pediatric Study on COVID-19 Vaccine

by Zacks Equity Research

Moderna is developing its COVID-19 vaccine, mRNA-1273, for different patient populations. It is also developing booster vaccine candidates as well as a next-generation COVID vaccine.